WASHINGTON — President Donald Trump’s nomination of Dr. Heidi Overton to serve as commissioner of the Food and Drug Administration faces growing uncertainty on Capitol Hill, where key Republican senators remain undecided ahead of a scheduled committee vote next week.
Overton, a preventive medicine physician currently serving as a White House domestic policy official, must secure approval from the Senate Health, Education, Labor and Pensions Committee before her nomination can advance to a full Senate vote. However, with Democrats set to take control of the Senate on Jan. 3, time is short for the administration to shepherd her nomination through the closely divided panel.
GOP Senators Remain Uncommitted
To advance out of the 21-member HELP Committee, Overton needs at least 11 votes. Assuming unified opposition from committee Democrats, she cannot afford to lose a single Republican vote. Yet several pivotal GOP senators have declined to publicly endorse her.
Sen. Susan Collins, R-Maine, said in a brief interview on Capitol Hill that she had not taken a position on the nomination, noting that she still needed “to get some answers on various things.” Sen. Lisa Murkowski, R-Alaska, also declined to state how she intends to vote. During Overton’s confirmation hearing in September, Murkowski pressed the nominee on political pressures surrounding access to mifepristone, the medication abortion pill.
Sen. Bill Cassidy, R-La., who chairs the HELP Committee, has also withheld his endorsement. Cassidy previously expressed strong concerns on social media regarding Overton’s nomination, citing a lack of managerial experience. In a post Wednesday, Cassidy said he remained undecided after holding “several frank conversations” with Overton and Jim O’Neill, Trump’s nominee to direct the National Science Foundation, regarding their roles, visions, and what he characterized as a lack of trust stemming from broken promises by other administration officials.
Controversies and Outside Opposition
If confirmed, Overton would take charge of an agency that has been without a permanent leader since Dr. Marty Makary resigned in May. The FDA is currently conducting a safety review of mifepristone that is set to conclude in March.
Overton’s background and past statements have drawn intense scrutiny from Democrats and external medical organizations. While working at the America First Policy Institute, a conservative think tank, she characterized the FDA’s decision allowing mail delivery of mifepristone as “dangerous to women.” During her September confirmation hearing, Overton sidestepped direct questions regarding the pill, stating that it had met FDA standards and asserting that she did not want to prejudge the agency’s review.
Outside groups have also mobilized against her nomination. Physicians for Reproductive Health and the National Abortion Federation sent a joint letter to members of the HELP Committee urging them to reject her appointment. A total of 370 health care professionals signed onto the effort, stating in their letter that Overton lacks commitment to evidence-based research and warning that she would “threaten access to reproductive health care, and endanger public health at large.”
During her September hearing, Overton appeared alongside Trump when he signed an executive order intended to reduce the number of vaccines routinely recommended for children. However, she appeared to break with Health and Human Services Secretary Robert F. Kennedy Jr. by publicly describing the measles, mumps and rubella vaccine as safe and effective.
Tight Timeline Before Senate Turnover
The White House has not responded to requests for comment regarding Overton’s nomination and has given no indication that it plans to withdraw her name.
If the HELP Committee fails to approve Overton or if the full Senate does not confirm her before Jan. 3, her nomination would likely be returned to the White House under Senate rules. In that scenario, Trump would be forced to renominate her before a Democratic-controlled Senate, where her confirmation prospects would be slim.



